ORPHA:494448
Vulvar squamous cell carcinoma
Also known as: Squamous cell carcinoma of the vulva
Publications
2,625
Trials
25
Interventional, condition-specific
Researchers
1,122
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare vulvar carcinoma characterized by an ulcer, nodule, macule, or pedunculated mass which is histologically composed of infiltrating islands of malignant squamous cells. Histological subtypes include keratinizing, non-keratinizing, basaloid, warty, and verrucous carcinomas. Some tumors are associated with human papilloma virus, smoking, high grade squamous intraepithelial lesion, chronic vulvar inflammatory disorders, or differentiated vulvar intraepithelial neoplasia. Patients may present with discharge, bleeding, or pain. Most important prognostic features are tumor depth and lymph node status.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0024609
- UMLS:C0280856
- NCIT:C4052
Additional Mondo synonyms (14)
epidermoid carcinoma of the vulva · epidermoid carcinoma of vulva · epidermoid cell carcinoma of the vulva · epidermoid cell carcinoma of vulva · mammalian vulva squamous cell carcinoma · squamous cell carcinoma of the vulva · squamous cell carcinoma of vulva · vulva epidermoid carcinoma · vulva epidermoid cell carcinoma · vulva squamous cell carcinoma · vulvar epidermoid carcinoma · vulvar epidermoid cell carcinoma · vulvar squamous cell cancer · vulvar squamous cell carcinoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
2,625 matched papers (1,414 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
25 matched on ClinicalTrials.gov (12 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
11
Drugs / clinical candidates · MONDO_0024609
- CEMIPLIMAB·phase 2
- CISPLATIN·phase 2
- ERLOTINIB·phase 2
- GEMCITABINE·phase 2
- IPILIMUMAB·phase 2
- LENVATINIB·phase 2
- NIVOLUMAB·phase 2
- PEMBROLIZUMAB·phase 2
- VORINOSTAT·phase 2
- DURVALUMAB·phase 1 2
- TREMELIMUMAB·phase 1 2
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
2,625
2,625 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
2,625 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1,414 in the last 10 years · low confidence
Phrase hits: 2,625 · MeSH hits: 0
Who's working on it?
1,122
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Nigdelis MP8 papers · 2026
Department of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Medical Center (UKS), 66424 Homburg, Germany.
Papers in Europe PMC - 02Wagner M8 papers · 2026
Department of General and Special Pathology, Saarland University (USAAR) and Saarland University Medical Center (UKS), 66424 Homburg, Germany.
Papers in Europe PMC - 03Hasenburg A7 papers · 2026
Department of Obstetrics and Gynecology, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
Papers in Europe PMC - 04Hoang L7 papers · 2026
Vancouver General Hospital, University of British Columbia, Vancouver, Canada.
Papers in Europe PMC - 05Klamminger GG7 papers · 2026
Department of General and Special Pathology, Saarland University (USAAR) and Saarland University Medical Center (UKS), 66424 Homburg, Germany.
Papers in Europe PMC - 06Bitterlich A6 papers · 2025
Department of General and Special Pathology, Saarland University (USAAR) and Saarland University Medical Center (UKS), 66424 Homburg, Germany.
Papers in Europe PMC - 07Solomayer EF6 papers · 2025
Department of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Medical Center (UKS), 66424 Homburg, Germany.
Papers in Europe PMC - 08Bleeker MCG5 papers · 2026
Amsterdam UMC location Vrije Universiteit Amsterdam, Pathology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands. Electronic address: mcg.bleeker@amsterdamumc.nl.
Papers in Europe PMC - 09Carreras-Dieguez N5 papers · 2025
Department of Obstetrics and Gynecology, Hospital Clínic - University of Barcelona, Barcelona, Spain
Papers in Europe PMC - 10
Clinical research
Is a treatment being tested?
25
interventional trials for this specific condition
25 interventional trials matched this specific condition name; 12 currently recruiting in our sample. 2,532 trials are registered for squamous cell carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
25 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 95.5th percentile).
low confidence · 95.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
25 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07672782·NOT YET RECRUITING·Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva
Not reviewed·Conditions: Vulvar Carcinoma · Recurrent or Metastatic Vulvar Cancer · Squamous Cell Carcinoma Vulva·Matched via name phrase
- NCT05905315·RECRUITING·Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC
Not reviewed·Conditions: Locally Advanced Vulvar Carcinoma · Squamous Cell Carcinoma of the Vulva·Matched via name phrase
- NCT07679841·NOT YET RECRUITING·Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma Patients
Not reviewed·Conditions: Vulvar Squamous Cell Carcinoma·Matched via name phrase
- NCT06202339·NOT YET RECRUITING·Alpha Radiation Emitters Device for the Treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva (DaRT).
Not reviewed·Conditions: Carcinoma of the Vulva · Recurrent Carcinoma of the Vulva·Matched via name phrase
- NCT04192253·RECRUITING·Treatment of Locally Advanced VULvar CArcinoma in a Neoadjuvant Setting With Carboplatin and Paclitaxel Chemotherapy (VULCANize)
Not reviewed·Conditions: Locally Advanced, Squamous Cell Carcinoma of the Vulva·Matched via name phrase
- NCT05639972·RECRUITING·E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Not reviewed·Conditions: HPV-Associated Cervical Carcinoma · HPV-Related Carcinoma · HPV-Related Malignancy · HPV Positive Oropharyngeal Squamous Cell Carcinoma·Matched via name phrase
- NCT07217171·RECRUITING·A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Not reviewed·Conditions: Bladder Cancer · Squamous Cell Carcinoma of the Lung · Esophageal Squamous Cell Carcinoma · Tongue Squamous Cell Carcinoma·Matched via name phrase
- NCT06358469·RECRUITING·STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision
Not reviewed·Conditions: Vulvar Squamous Cell Carcinoma·Matched via name phrase
- NCT06505551·NOT YET RECRUITING·Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma
Not reviewed·Conditions: HPV-Related Squamous Cell Carcinoma · HPV-Related Cervical Squamous Cell Carcinoma · HPV-Related Vulvar Squamous Cell Carcinoma · HPV-Related Penile Squamous Cell Carcinoma·Matched via name phrase
- NCT05686226·RECRUITING·E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Not reviewed·Conditions: Cervical Cancer · Throat Cancer · Oropharynx Cancer · Anal Cancer·Matched via name phrase
- NCT04161664·RECRUITING·Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy
Not reviewed·Conditions: Metastatic Squamous Cell Carcinoma of the Vulva·Matched via name phrase
- NCT05576831·RECRUITING·STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision
Not reviewed·Conditions: Vulvar Cancer·Matched via name phrase
Broader category: squamous cell carcinoma
2,532
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06662058·RECRUITING·Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Not reviewed·Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Cutaneous Squamous Cell Carcinoma of the Head and Neck · Head and Neck Carcinoma of Unknown Primary · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT06540443·RECRUITING·Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Lymph Node Metastasis·Matched via name phrase
- NCT06599775·NOT YET RECRUITING·Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer
Not reviewed·Conditions: Resectable Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT07173270·NOT YET RECRUITING·Improved Oral Health in Head and Neck Cancer Survivors
Not reviewed·Conditions: Head and Neck Cancer Squamous Cell Carcinoma · Head and Neck Cancer·Matched via name phrase
- NCT07487896·RECRUITING·A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
Not reviewed·Conditions: Advanced Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT06659146·RECRUITING·Thermotherapy in Addition to SOC Palliative Radiotherapy
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Cutaneous Squamous Cell Carcinoma · Breast Cancer Recurrent·Matched via name phrase
- NCT07726199·RECRUITING·Study Comparing Different Neck Treatment Approaches in Patients With Oral Cancer Without Visible Neck Spread
Not reviewed·Conditions: Oral Squamous Cell Carcinoma (OSCC)·Matched via name phrase
- NCT06589609·RECRUITING·Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer
Not reviewed·Conditions: Oropharyngeal Squamous Cell Carcinoma (SCC)·Matched via name phrase
- NCT06161532·RECRUITING·Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Not reviewed·Conditions: Small Cell Carcinoma of the Bladder · Small Cell Carcinoma of the Urinary Tract · Squamous Cell Carcinoma of the Bladder · Squamous Cell Carcinoma of the Urinary Tract·Matched via name phrase
- NCT06915454·RECRUITING·High-Resolution PET-CT Imaging for Surgical Margin Visualization
Not reviewed·Conditions: Cancer · Solid Malignant Tumors · SCC - Squamous Cell Carcinoma · HNSCC·Matched via name phrase
- NCT06693323·RECRUITING·Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC
Not reviewed·Conditions: HNSCC · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT07629817·NOT YET RECRUITING·Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT06648096·RECRUITING·Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Not reviewed·Conditions: Fanconi Anemia · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT07392580·RECRUITING·Intralesional Chemotherapy (IC): Cisplatin + Epinephrine
Not reviewed·Conditions: Laryngeal Squamous Cell Carcinoma·Matched via name phrase
- NCT05747625·RECRUITING·(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Metastatic Head and Neck Squamous Cell Carcinoma · Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck·Matched via name phrase
Observational and natural-history studies
5 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06911801·NOT YET RECRUITING·In Vitro Study of [18F]F-FAPI-74 Feasibility in Vulvar Cancer
Not reviewed·Conditions: Vulvar Squamous Cell Carcinoma·Matched via name phrase
- NCT06039111·RECRUITING·Indocyanine Green for Detection of Sentinel Lymph Nodes In Comparison to ICG Plus Technetium in the Evaluation of Vulvar Squamous Cell Carcinoma
Not reviewed·Conditions: Vulvar Cancer·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 9 · after dedupe 9 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 9 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (9)
- isrctn·ISRCTN72275160·No longer recruiting·Proactive against reactive treatment for lichen sclerosus
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15057626·No longer recruiting·Comparing surgical techniques for removal of the groin lymph nodes in the treatment of vulvar cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN37773303·No longer recruiting·GROningen INternational Study on Sentinel nodes in Vulvar cancer. An observational study.
skipped — LLM skipped (--skip-llm)
- ctis·2025-524759-29-00·Authorised·COLOMBE - A multicentre, single arm, phase 1/2 study, aiming to assess the safety and efficacy of nivolumab and imiquimod combination in vulvar squamous cell carcinoma patients
skipped — LLM skipped (--skip-llm)
- ctis·2024-512862-32-00·Cancelled·(APOLLO)Neo-adjuvant Pembrolizumab in vulvar squamous cell carcinoma: a clinical proof-of-concept study
skipped — LLM skipped (--skip-llm)
- ctis·2022-501253-37-00·Expired·A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE-158)
skipped — LLM skipped (--skip-llm)
- ctis·2023-508126-95-00·Authorised, ongoing·A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and its Anti-tumour Effect in Adult Patients with CD44v6 Expressing Solid Tumours
skipped — LLM skipped (--skip-llm)
- ctis·2024-514920-18-00·Cancelled·ABIMMUNE: A Phase I/II study evaluating the safety and clinical activity of anti-PDL1 (Durvalumab [MEDI4736]) + Anti CTLA-4 (Tremelimumab) antibodies administrated in combination with stereotactic body radiotherapy (SBRT) in patients with metastatic squamous cell carcinoma of head and neck, lung, oesophageus, cervix, vagina, vulva or anus.
skipped — LLM skipped (--skip-llm)
- ctis·2023-510320-71-00·Cancelled·PEVOsq: Phase II basket trial evaluating the efficacy of a combination of pembrolizumab and vorinostat in patients with recurrent and/or metastatic squamous cell carcinoma
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Vulvar squamous cell carcinoma — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Vulvar squamous cell carcinoma" OR "Squamous cell carcinoma of the vulva" OR "Squamous cell carcinoma of vulva" OR "epidermoid carcinoma of the vulva" OR "epidermoid carcinoma of vulva" OR "epidermoid cell carcinoma of the vulva" OR "epidermoid cell carcinoma of vulva" OR "mammalian vulva squamous cell carcinoma" OR "vulva epidermoid carcinoma" OR "vulva epidermoid cell carcinoma" OR "vulva squamous cell carcinoma" OR "vulvar epidermoid carcinoma" OR "vulvar epidermoid cell carcinoma" OR "vulvar squamous cell cancer"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Vulvar squamous cell carcinoma" OR "Squamous cell carcinoma of the vulva" OR "Squamous cell carcinoma of vulva" OR "epidermoid carcinoma of the vulva" OR "epidermoid carcinoma of vulva" OR "epidermoid cell carcinoma of the vulva" OR "epidermoid cell carcinoma of vulva" OR "mammalian vulva squamous cell carcinoma" OR "vulva epidermoid carcinoma" OR "vulva epidermoid cell carcinoma" OR "vulva squamous cell carcinoma" OR "vulvar epidermoid carcinoma" OR "vulvar epidermoid cell carcinoma" OR "vulvar squamous cell cancer"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 25 interventional · 5 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"squamous cell carcinoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (2625) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T17:31:52.015Z
